NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease
| dc.Affiliation | October university for modern sciences and Arts MSA | |
| dc.contributor.author | Painuli, Sakshi | |
| dc.contributor.author | Semwal, Prabhakar | |
| dc.contributor.author | Zam, Wissam | |
| dc.contributor.author | Taheri, Yasaman | |
| dc.contributor.author | Ezzat, Shahira M | |
| dc.contributor.author | Zuo, Peijun | |
| dc.contributor.author | Li, Liping | |
| dc.contributor.author | Kumar, Dileep | |
| dc.contributor.author | Sharifi-Rad, Javad | |
| dc.contributor.author | Cruz-Martins, Natália | |
| dc.date.accessioned | 2023-03-06T08:38:58Z | |
| dc.date.available | 2023-03-06T08:38:58Z | |
| dc.date.issued | 2023-03-02 | |
| dc.description | SJR 2024 0.361 Q3 H-Index 73 | |
| dc.description.abstract | Alzheimer's disease (AD) is an increasingly common neurodegenerative disease that attracts the attention of researchers and medical community in order to develop new, safe and more effective drugs. Currently available drugs could only slow the AD progression and relieve the symptoms, in addition to being linked to moderate-to-severe side effects. N-methyl D-aspartate (NMDA) receptors antagonists were reported to have the ability to block the glutamate-mediated excitotoxic activity being good therapeutic targets for several neurodegenerative diseases, including AD. Based on data obtained so far, this review provides an overview over the use of NMDA antagonists for AD treatment, starting with a key emphasis on present features and future aspects regarding the use of NMDA antagonists for AD, and lastly a key focus is also given on its use in precision medicine. | en_US |
| dc.description.uri | https://www.scimagojr.com/journalsearch.php?q=23453&tip=sid&clean=0 | |
| dc.identifier.citation | Sharifi-Rad, J., Cruz-Martins, N., Painuli, S., Semwal, P., Zam, W., Taheri, Y., Ezzat, S. M., Zuo, P., Li, L., & Kumar, D. (2022). WITHDRAWN: NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer Disease. Combinatorial Chemistry & High Throughput Screening, 25. https://doi.org/10.2174/1386207325666220428112541 | |
| dc.identifier.doi | https://doi.org/10.2174/1386207325666220428112541 | |
| dc.identifier.other | 10.2174/1386207325666220428112541 | |
| dc.identifier.uri | http://repository.msa.edu.eg/xmlui/handle/123456789/5411 | |
| dc.language.iso | en_US | en_US |
| dc.publisher | Bentham Science Publishers B.V. | en_US |
| dc.relation.ispartofseries | Combinatorial Chemistry & High Throughput Screening;Volume 26, Issue 12, 2023 | |
| dc.subject | Alzheimer’s disease, | en_US |
| dc.subject | neurodegeneration, | en_US |
| dc.subject | N-methyl D-aspartate (NMDA) receptors | en_US |
| dc.subject | precision medicine | en_US |
| dc.title | NMDA Inhibitors: A Potential Contrivance to Assist in Management of Alzheimer’s Disease | en_US |
| dc.type | Article | en_US |
